A Two-Step Approach for the Design and Generation of Nanobodies

Nanobodies, the smallest possible antibody format, have become of considerable interest for biotechnological and immunotherapeutic applications. They show excellent robustness, are non-immunogenic in humans, and can easily be engineered and produced in prokaryotic hosts. Traditionally, nanobodies are selected from camelid immune libraries involving the maintenance and treatment of animals. Recent advances have involved the generation of nanobodies from naïve or synthetic libraries. However, such approaches demand large library sizes and sophisticated selection procedures. Here, we propose an alternative, two-step approach for the design and generation of nanobodies. In a first step, complementarity-determining regions (CDRs) are grafted from conventional antibody formats onto nanobody frameworks, generating weak antigen binders. In a second step, the weak binders serve as templates to design focused synthetic phage libraries for affinity maturation. We validated this approach by grafting toxin- and hapten-specific CDRs onto frameworks derived from variable domains of camelid heavy-chain-only antibodies (VHH). We then affinity matured the hapten binder via panning of a synthetic phage library. We suggest that this strategy can complement existing immune, naïve, and synthetic library based methods, requiring neither animal experiments, nor large libraries, nor sophisticated selection protocols.

[1]  S. Tzipori,et al.  Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents , 2009, Infection and Immunity.

[2]  Stefan Ståhl,et al.  Affibody Molecules in Biotechnological and Medical Applications. , 2017, Trends in biotechnology.

[3]  A. Skerra,et al.  Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Rajabibazl,et al.  In Vivo Neutralization of Botulinum Neurotoxins Serotype E with Heavy-chain Camelid Antibodies (VHH) , 2013, Molecular Biotechnology.

[5]  Nick Devoogdt,et al.  (18)F-nanobody for PET imaging of HER2 overexpressing tumors. , 2016, Nuclear medicine and biology.

[6]  S. Tzipori,et al.  A Single VHH-Based Toxin-Neutralizing Agent and an Effector Antibody Protect Mice against Challenge with Shiga Toxins 1 and 2 , 2013, Infection and Immunity.

[7]  A. Plückthun,et al.  Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. , 2001, Journal of molecular biology.

[8]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[9]  Andreas Plückthun,et al.  Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.

[10]  S. Fanning,et al.  An anti‐hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop , 2011, Protein science : a publication of the Protein Society.

[11]  Heinrich Leonhardt,et al.  Targeting and tracing antigens in live cells with fluorescent nanobodies , 2006, Nature Methods.

[12]  M. Xian,et al.  Recent advances in the selection and identification of antigen‐specific nanobodies , 2018, Molecular immunology.

[13]  Shenghua Li,et al.  Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. , 2003, Journal of immunological methods.

[14]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[16]  Frederic A. Fellouse,et al.  Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. , 2004, Journal of molecular biology.

[17]  Serge Muyldermans,et al.  Nanobodies as Probes for Protein Dynamics in Vitro and in Cells* , 2015, The Journal of Biological Chemistry.

[18]  N. Bec,et al.  A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm , 2007, BMC biotechnology.

[19]  Tristan J. Vaughan,et al.  Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library , 1996, Nature Biotechnology.

[20]  J. R. Horn,et al.  Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  W. Marasco,et al.  The growth and potential of human antiviral monoclonal antibody therapeutics , 2007, Nature Biotechnology.

[22]  B. Jilma,et al.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. , 2016, The New England journal of medicine.

[23]  Bruce D Hammock,et al.  Isolation of alpaca anti-hapten heavy chain single domain antibodies for development of sensitive immunoassay. , 2012, Analytical chemistry.

[24]  J. Hubbell,et al.  Covalently conjugated VEGF--fibrin matrices for endothelialization. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  A. Bhunia,et al.  Deoxynivalenol-mimic nanobody isolated from a naïve phage display nanobody library and its application in immunoassay. , 2015, Analytica chimica acta.

[26]  A. Plückthun,et al.  Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. , 2000, Journal of molecular biology.

[27]  S. Muyldermans,et al.  VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. , 2008, Molecular immunology.

[28]  A. Brunger,et al.  A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. , 2008, Structure.

[29]  Hennie R. Hoogenboom,et al.  A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies* , 1999, The Journal of Biological Chemistry.

[30]  Jakub Toczek,et al.  Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.

[31]  Yakun Wan,et al.  Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications , 2014, Journal of Translational Medicine.

[32]  Jacques Barbet,et al.  Generation of llama single-domain antibodies against methotrexate, a prototypical hapten. , 2007, Molecular immunology.

[33]  S. Muyldermans,et al.  General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold* , 2009, Journal of Biological Chemistry.

[34]  J. Bluestone,et al.  CD3-specific antibodies: a portal to the treatment of autoimmunity , 2007, Nature Reviews Immunology.

[35]  C. Shoemaker,et al.  Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). , 2007, Journal of immunological methods.

[36]  Conor McMahon,et al.  Yeast surface display platform for rapid discovery of conformationally selective nanobodies , 2018, Nature Structural & Molecular Biology.

[37]  L. Wyns,et al.  Camelid immunoglobulins and nanobody technology. , 2009, Veterinary immunology and immunopathology.

[38]  P. Stewart,et al.  Targeting G protein-coupled receptor signaling at the G protein level with a selective nanobody inhibitor , 2018, Nature Communications.

[39]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[40]  R. Zeldin,et al.  Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura , 2017, Journal of thrombosis and haemostasis : JTH.

[41]  Andrew D. Griffiths,et al.  By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling , 1992, Bio/Technology.

[42]  C. Eigenbrot,et al.  High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. , 2004, Journal of molecular biology.

[43]  J. Rain,et al.  NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies , 2016, eLife.

[44]  Shohei Koide,et al.  A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain , 2010, Nature Structural &Molecular Biology.

[45]  Pauline M Rudd,et al.  The impact of glycosylation on the biological function and structure of human immunoglobulins. , 2007, Annual review of immunology.

[46]  Claudia Sheedy,et al.  Selection, characterization, and CDR shuffling of naive llama single-domain antibodies selected against auxin and their cross-reactivity with auxinic herbicides from four chemical families. , 2006, Journal of agricultural and food chemistry.

[47]  H. Ploegh,et al.  Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma. , 2016, Angewandte Chemie.

[48]  Frederic A. Fellouse,et al.  High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. , 2007, Journal of molecular biology.

[49]  Yang Xu,et al.  Isolation and characterisation of deoxynivalenol affinity binders from a phage display library based on single-domain camelid heavy chain antibodies (VHHs) , 2012 .

[50]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[51]  Andrew J. Martin,et al.  Antibody-antigen interactions: contact analysis and binding site topography. , 1996, Journal of molecular biology.

[52]  Mitchell Ho,et al.  Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples , 2017, mAbs.

[53]  S. Muyldermans,et al.  A general protocol for the generation of Nanobodies for structural biology , 2014, Nature Protocols.

[54]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[55]  B. Hammock,et al.  VHH antibodies: emerging reagents for the analysis of environmental chemicals , 2016, Analytical and Bioanalytical Chemistry.

[56]  L. Wyns,et al.  Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. , 2005, Journal of molecular biology.

[57]  Yakun Wan,et al.  Generation of Small Single Domain Nanobody Binders for Sensitive Detection of Testosterone by Electrochemical Impedance Spectroscopy. , 2016, ACS applied materials & interfaces.

[58]  Sachdev S Sidhu,et al.  Molecular recognition by a binary code. , 2005, Journal of molecular biology.

[59]  B. Hammock,et al.  Competitive selection from single domain antibody libraries allows isolation of high-affinity antihapten antibodies that are not favored in the llama immune response. , 2011, Analytical chemistry.

[60]  S. Muyldermans,et al.  Nanobody®-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites , 2012, Nucleic acids research.

[61]  G. Oyler,et al.  Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. , 2010, Toxicon : official journal of the International Society on Toxinology.

[62]  Corella S. Casas-Delucchi,et al.  Modulation of protein properties in living cells using nanobodies , 2010, Nature Structural &Molecular Biology.

[63]  M. Uhlén,et al.  Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain , 1997, Nature Biotechnology.

[64]  Ira Mellman,et al.  Antibody Therapeutics in Cancer , 2013, Science.

[65]  H. Persson,et al.  A focused antibody library for improved hapten recognition. , 2006, Journal of molecular biology.

[66]  H. S. de Bruijn,et al.  EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[67]  J. Reichert,et al.  Antibodies to watch in 2018 , 2018, mAbs.

[68]  David G. Williams,et al.  Humanising Antibodies by CDR Grafting , 2001 .

[69]  S. Daunert,et al.  Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis. , 2017, Annual review of analytical chemistry.

[70]  H. Ploegh,et al.  Exploiting Nanobodies' Singular Traits. , 2018, Annual review of immunology.